Logo image of MEDCL.PA

MEDINCELL SA (MEDCL.PA) Stock Fundamental Analysis

Europe - EPA:MEDCL - FR0004065605 - Common Stock

21.08 EUR
-0.16 (-0.75%)
Last: 9/22/2025, 12:04:27 PM
Fundamental Rating

4

Taking everything into account, MEDCL scores 4 out of 10 in our fundamental rating. MEDCL was compared to 50 industry peers in the Pharmaceuticals industry. MEDCL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MEDCL is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MEDCL has reported negative net income.
In the past year MEDCL had a positive cash flow from operations.
In the past 5 years MEDCL always reported negative net income.
MEDCL had negative operating cash flow in 4 of the past 5 years.
MEDCL.PA Yearly Net Income VS EBIT VS OCF VS FCFMEDCL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M -20M -30M

1.2 Ratios

MEDCL has a worse Return On Assets (-20.38%) than 80.00% of its industry peers.
Industry RankSector Rank
ROA -20.38%
ROE N/A
ROIC N/A
ROA(3y)-65.75%
ROA(5y)-56.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MEDCL.PA Yearly ROA, ROE, ROICMEDCL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

MEDCL has a better Gross Margin (95.46%) than 94.00% of its industry peers.
In the last couple of years the Gross Margin of MEDCL has grown nicely.
The Profit Margin and Operating Margin are not available for MEDCL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.72%
GM growth 5Y7.65%
MEDCL.PA Yearly Profit, Operating, Gross MarginsMEDCL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

MEDCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MEDCL has more shares outstanding
MEDCL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MEDCL has an improved debt to assets ratio.
MEDCL.PA Yearly Shares OutstandingMEDCL.PA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
MEDCL.PA Yearly Total Debt VS Total AssetsMEDCL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

MEDCL has an Altman-Z score of 3.16. This indicates that MEDCL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.16, MEDCL is in line with its industry, outperforming 50.00% of the companies in the same industry.
MEDCL has a debt to FCF ratio of 3.30. This is a good value and a sign of high solvency as MEDCL would need 3.30 years to pay back of all of its debts.
MEDCL has a better Debt to FCF ratio (3.30) than 64.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.3
Altman-Z 3.16
ROIC/WACCN/A
WACC7.6%
MEDCL.PA Yearly LT Debt VS Equity VS FCFMEDCL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 2.70 indicates that MEDCL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.70, MEDCL belongs to the top of the industry, outperforming 88.00% of the companies in the same industry.
A Quick Ratio of 2.70 indicates that MEDCL has no problem at all paying its short term obligations.
MEDCL's Quick ratio of 2.70 is amongst the best of the industry. MEDCL outperforms 90.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 2.7
MEDCL.PA Yearly Current Assets VS Current LiabilitesMEDCL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

MEDCL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.16%, which is quite impressive.
Looking at the last year, MEDCL shows a very strong growth in Revenue. The Revenue has grown by 181.43%.
Measured over the past years, MEDCL shows a very strong growth in Revenue. The Revenue has been growing by 54.88% on average per year.
EPS 1Y (TTM)28.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.59%
Revenue 1Y (TTM)181.43%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%720.66%

3.2 Future

MEDCL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.89% yearly.
Based on estimates for the next years, MEDCL will show a very strong growth in Revenue. The Revenue will grow by 39.80% on average per year.
EPS Next Y81.81%
EPS Next 2Y97.83%
EPS Next 3Y59.89%
EPS Next 5Y49.89%
Revenue Next Year14.84%
Revenue Next 2Y71.41%
Revenue Next 3Y64.07%
Revenue Next 5Y39.8%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MEDCL.PA Yearly Revenue VS EstimatesMEDCL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
MEDCL.PA Yearly EPS VS EstimatesMEDCL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MEDCL. In the last year negative earnings were reported.
Also next year MEDCL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MEDCL.PA Price Earnings VS Forward Price EarningsMEDCL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

The rest of the industry has a similar Price/Free Cash Flow ratio as MEDCL.
Industry RankSector Rank
P/FCF 39.19
EV/EBITDA N/A
MEDCL.PA Per share dataMEDCL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

4.3 Compensation for Growth

MEDCL's earnings are expected to grow with 59.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y97.83%
EPS Next 3Y59.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MEDCL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDINCELL SA

EPA:MEDCL (9/22/2025, 12:04:27 PM)

21.08

-0.16 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-17 2025-06-17/amc
Earnings (Next)12-09 2025-12-09
Inst Owners29.31%
Inst Owner ChangeN/A
Ins Owners3.53%
Ins Owner ChangeN/A
Market Cap697.75M
Analysts86.25
Price Target23.63 (12.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.18%
PT rev (3m)6.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-146.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-12.4%
Revenue NY rev (3m)-37.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.45
P/FCF 39.19
P/OCF 35.84
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)0.54
FCFY2.55%
OCF(TTM)0.59
OCFY2.79%
SpS0.77
BVpS-0.49
TBVpS-0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.38%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.46%
FCFM 70.05%
ROA(3y)-65.75%
ROA(5y)-56.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.72%
GM growth 5Y7.65%
F-Score7
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.3
Debt/EBITDA N/A
Cap/Depr 83.42%
Cap/Sales 6.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.7
Quick Ratio 2.7
Altman-Z 3.16
F-Score7
WACC7.6%
ROIC/WACCN/A
Cap/Depr(3y)71.46%
Cap/Depr(5y)81.14%
Cap/Sales(3y)10.03%
Cap/Sales(5y)17.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.59%
EPS Next Y81.81%
EPS Next 2Y97.83%
EPS Next 3Y59.89%
EPS Next 5Y49.89%
Revenue 1Y (TTM)181.43%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%720.66%
Revenue Next Year14.84%
Revenue Next 2Y71.41%
Revenue Next 3Y64.07%
Revenue Next 5Y39.8%
EBIT growth 1Y48.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year316.92%
EBIT Next 3Y96.39%
EBIT Next 5YN/A
FCF growth 1Y235.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y263.28%
OCF growth 3YN/A
OCF growth 5YN/A